Welcome to our dedicated page for Kane Biotech news (Ticker: KNBIF), a resource for investors and traders seeking the latest updates and insights on Kane Biotech stock.
Kane Biotech Inc. (KNBIF, TSX-V: KNE) generates news primarily around its wound care biotechnology activities, especially the development and clinical use of its revyve ae Antimicrobial Wound Gel and Wound Gel Spray. Company updates frequently highlight how these products are designed to disrupt biofilms and address wound bacteria, which Kane Biotech identifies as key contributors to antibiotic resistance and complex wound outcomes.
News releases often cover regulatory milestones, such as FDA 510(k) clearances for revyve Antimicrobial Wound Gel and Spray, Health Canada approvals for the gel and spray, and the submission of a 510(k) application for revyve Antimicrobial Wound Cleanser. Investors and clinicians can also follow announcements about clinical and pre-clinical data, including case series in diabetic foot ulcers, burn wounds, chronic radiation-induced ulcers, venous leg ulcers, and other challenging wound types.
Kane Biotech regularly reports participation in wound care and burn conferences, where it presents data on healing trajectories, infection control, and biofilm management using revyve products. These events include meetings such as the Symposium on Advanced Wound Care, Diabetic Foot Conference, Southern Region Burn Conference, Innovations in Wound Healing, and other specialized gatherings.
In addition, the company issues news on financing and corporate developments, including private placement offerings, financial results, board and committee changes, and interactions with funding partners. For readers tracking KNBIF, this news page provides a centralized view of Kane Biotech’s scientific, regulatory, clinical, and corporate announcements related to its wound care biotechnology focus.
Kane Biotech has entered into collaborations with Dr. James Doub and the University of Texas Medical Branch to investigate the application of DispersinB® for treating Prosthetic Joint Infections (PJI). Supported by funding from the National Institutes of Health (NIH), the research aims to address crucial challenges in treating PJIs, which affect 1-2% of prostheses and are projected to cost the U.S. healthcare system $1.62 billion in 2020 alone. CEO Marc Edwards emphasized the importance of these collaborations for advancing treatment strategies, highlighting the distinct advantages of DispersinB®.
Kane Biotech announces a new video blog series aimed at enhancing investor communication, a part of their 2022 commitment. CEO Marc Edwards emphasized the company's 20-year expertise in biofilm research, positioning it favorably in the wound care market, with significant opportunities for commercialization. Key milestones to watch include the start of human clinical trials for DispersinB® wound gel in Q2 2022, the anticipated launch of coactiv+™ wound gel, and the establishment of a commercial partnership to boost market access.
Kane Biotech reported third quarter 2021 financial results with revenue of $438,016, a 53% increase from $286,934 in Q3 2020, driven by new major pet retail customer sales. License revenue soared 114% compared to the previous year. However, total operating expenses rose 38% to $1,721,305, leading to a net loss of ($1,582,959), up 53% from the prior year. As of September 30, 2021, cash reserves were $1,292,623, reflecting growth from $1,007,923 at year-end 2020.
Kane Biotech Inc. (OTCQB: KNBIF) will announce its third quarter 2021 financial results on November 16, 2021, after market close. The conference call to discuss the results and business developments will occur at 4:30 p.m. ET. Kane Biotech focuses on research and commercialization of technologies to combat microbial biofilms and holds 52 patents, as well as trademarks for several products. Investors can access the call via telephone or webcast, with the details provided in the press release.
Kane Biotech Inc. (OTCQB: KNBIF) announced a new credit agreement with Pivot Financial, increasing its credit facility from $1.48 million to $2.5 million. The funds will support research and development, cover expenses related to STEM Animal Health Inc., and provide working capital. CFO Ray Dupuis emphasized that this facility enhances the company's liquidity during ongoing partnership discussions. Pivot Financial's President, Dan Flaro, noted the improved terms, which facilitate the commercialization of Kane Biotech's intellectual property, comprising 52 patents and trademarks.
Kane Biotech Inc. has announced the shipment of its first order of bluestem™ oral care products to PetSmart Canada. These products will be available in all 150 PetSmart stores and online, aimed at improving pet oral health by combating harmful biofilms like plaque and tartar.
Developed by STEM Animal Health Inc., a joint venture between Kane Biotech and Animalcare Group PLC, bluestem™ utilizes coactiv+™ technology to effectively reduce tartar without harsh chemicals. Kane Biotech is traded under the symbols KNE on TSX and KNBIF on OTCQB.
Kane Biotech (KNBIF) reported its Q2 2021 results, showcasing a revenue increase to $278,741, up from $267,493 in Q2 2020. However, gross profit fell to $83,584 compared to $115,570 in the previous year, while operating expenses surged to $1,090,396 from $711,448. This led to a loss from operations of ($1,006,812), compared to ($595,878) in Q2 2020. The CEO expressed optimism about growth in animal health, OTC/dermatology, and wound care, and highlighted recent patent grants and new partnerships. The company has also raised $1,116,000 in warrant exercises this year.
Kane Biotech is set to announce its Q2 2021 financial results on August 26, 2021, after market close. A conference call will be held at 4:30 p.m. ET to discuss these results and recent business developments. The company focuses on technologies aimed at preventing and removing microbial biofilms and boasts a solid portfolio with 54 patents. Kane Biotech operates under the stock symbols KNE on TSX Venture and KNBIF on OTCQB.
Kane Biotech has received two Decisions to Grant from the European Patent Office for its coactiv+™ technology, enhancing patent coverage for its wound and skin infection treatments. The granted patents cover proprietary formulations, expanding the scope and term of protection significantly. CEO Marc Edwards emphasized the technology's versatility across various applications, including personal care and wound healing. The coactiv+™ technology destabilizes biofilms to promote healing and is recognized as safe by the FDA, positioning Kane for commercialization opportunities.
Kane Biotech Inc. is expanding its wound care portfolio with a new antimicrobial hydrogel utilizing its coactiv+™ technology, aiming for quicker market access via the 510(k) regulatory pathway. The US market for wound care hydrogels is estimated at US$200M. This initiative aligns with Kane's strategy to leverage its biofilm research and intellectual property for developing treatments for biofilm-related infections.
Laboratory tests suggest coactiv+™ effectively inhibits bacterial biofilm formation, making it a promising addition to wound healing products.
FAQ
What is the current stock price of Kane Biotech (KNBIF)?
What is the market cap of Kane Biotech (KNBIF)?
